Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew P. Frosch, M.D.,Ph.D.


This page shows the publications co-authored by Matthew Frosch and Simon Dujardin.
Connection Strength

  1. Impact of Sterilization Methods on the Seeding Ability of Human Tau Proteopathic Seeds. J Neuropathol Exp Neurol. 2021 10 26; 80(10):912-921.
    View in: PubMed
    Score: 0.242
  2. Kinetics of tau aggregation reveals patient-specific tau characteristics among Alzheimer's cases. Brain Commun. 2021; 3(2):fcab096.
    View in: PubMed
    Score: 0.234
  3. Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons. J Neurosci. 2021 05 12; 41(19):4335-4348.
    View in: PubMed
    Score: 0.233
  4. Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat Med. 2021 Feb; 27(2):356.
    View in: PubMed
    Score: 0.230
  5. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat Med. 2020 08; 26(8):1256-1263.
    View in: PubMed
    Score: 0.220
  6. Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathol Commun. 2018 11 29; 6(1):132.
    View in: PubMed
    Score: 0.197
  7. Tau reduction in the presence of amyloid-ß prevents tau pathology and neuronal death in vivo. Brain. 2018 07 01; 141(7):2194-2212.
    View in: PubMed
    Score: 0.048
  8. Enhanced Tau Aggregation in the Presence of Amyloid ß. Am J Pathol. 2017 Jul; 187(7):1601-1612.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.